# ABBY (NCT04523857)

> ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04523857
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Abramson Cancer Center at Penn Medicine
- Conditions: Breast Cancer
- Interventions: Abemaciclib; Hydroxychloroquine
- Enrollment: 44
- Primary outcome: Incidence of treatment-emergent adverse events during cycle 1 of the safety cohort (safety of combination HCQ + Abema)
- Primary outcome: Change in bone marrow DTC number evaluated by DTC-IHC assay after 6 cycles of therapy compared to baseline (Efficacy of Abema +/- HCQ in eliminating bone marrow DTCs)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 27
- YouTube: 1
- X threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=abby-nct04523857

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04523857", "email": "<work email>"}; the inbox owner confirms by the emailed link.